Biostem Technologies Inc. (BSEM)
OTC PINK OTC PINK Primary 
BioStem Technologies, Inc. (BSEM) M&A Call Transcript
BioStem Technologies, Inc. (BSEM) M&A Call Transcript
BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care Business
Accelerates expansion of BioStem's commercial organization through integration of an experienced national sales force Expands access to major GPO networks, strengthening BioStem's position across hospital settings Barry Hassett promoted to Chief Commercial Officer Conference call scheduled for tomorrow, January 22nd at 8am ET POMPANO BEACH, FL, January 21, 2026 – PRISM MediaWire (Press Release Service
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
Decision ensures continued patient access to VENDAJE® and VENDAJE AC® POMPANO BEACH, Fla., Jan. 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
POMPANO BEACH, FL, December 18, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
Expanding its Portfolio with American Amnionto Serve the Wound Care Needs of Our Veterans BioStem Technologies launched two new placental-derived allografts—American Amnion and American Amnion AC—featuring its BioRetain processing technology. The products aim to enhance chronic wound healing with improved structural integrity and cell preservation, offering clinicians more consistent outcomes.
BioStem Technologies Expands Product Access in Medicaid
Florida Medicaid Adds BioStem's VENDAJEⓇ and VENDAJE ACⓇ to Covered Skin Substitutes List Key Takeaways POMPANO BEACH, Fla., Nov. 25, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies, Inc. (BSEM) Q3 2025 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Philip Taylor - Associate Jason Matuszewski - CEO, President, Secretary & Chairman Brandon Poe - CFO & Independent Director Conference Call Participants Bruce Jackson - The Benchmark Company, LLC, Research Division Eric Schlanger Kevin Bennett Presentation Operator Hello, and welcome to the BioStem Technologies Third Quarter 2025 Earnings Call. [Operator Instructions] I would now like to turn the conference over to Trip Taylor, Investor Relations.
BioStem Technologies Reports Third Quarter 2025 Financial Results
Key Takeaways POMPANO BEACH, FL, November 13, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported financial results for the third quarter ended September 30, 2025.
BioStem Technologies Announces Filing of Restated Financial Statements
Key Takeaways POMPANO BEACH, FL, November 13, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes
Key Takeaways POMPANO BEACH, Fla., November 5, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters
Future Relocation and Expansion to Create Up to 100 New Jobs Over 5 Years City Approves Up to $300,000 in Economic Incentives to Rapidly Growing MedTech Business POMPANO BEACH, Fla., Nov. 5, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers
Key Takeaways Randomized controlled trial results published in the International Journal of Tissue Repair demonstrate BioRetain® allografts significantly improve probability of achieving lasting wound closure versus standard of care POMPANO BEACH, Fla., October 31, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
